Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats

Stroke

Volumn 28, Issue 5, 1997, Pages 1060-1065

  Önal, M Zülküf ^a   Li, Fuhai ^a   Tatlisumak, Turgut ^a   Locke, Kenneth W ^c   Sandage Jr , Bobby W ^c   Fisher, Marc ^a,b  

^a Med Center of Central Massachusetts   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Interneuron Pharmaceuticals Inc   (United States)

Author keywords

cerebral ischemia, focal; citicoline; MK 801; neuroprotection; rats

Indexed keywords

CITICOLINE; DIZOCILPINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0343052709     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.5.1060     Document Type: Article

References (36)

1. Ginsberg MD. The concept of the therapeutic window: a synthesis of critical issues. In: Moskowitz MA, Caplan LR, eds. Cerebrovascular Diseases: Nineteenth Princeton Stroke Conference. Boston, Mass: Butterworth-Heinemann; 1995:331-351.
2. Fisher M. Bogousslavsky J. Evolving toward effective therapy for acute ischemic stroke. JAMA. 1993,270:360-364.
3. Weiss GB. Mini review: metabolism and actions of citicoline as an endogenous compound and administered exogenously as citicoline. Life Sci. 1995;56:637-660.
4. Foster AC, Wong EHF. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Phannacol. 1987;91:403-410.
5. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipids. J Biol Chem. 1956;222:193-214.
6. Kakihana M, Fukuda N, Suno M, Nagaoka A. Effects of citicoline in neurologic deficits and cerebral glucose metabolism in rat model of cerebral ischemia. Stroke. 1988;19:217-222.
7. Hamdorf G, Cervos-Navaro J. Therapeutic effect of orally applied cytidine diphosphate choline in mild and severe degrees of normobaric and normocapnic degrees of hypocapnia in rats. Arzneimittelforschung. 1991;41:1206-1210.
8. Hamdorf G, Cervos-Navaro J, Mueller R. Increase of survival time in experimental hypoxia by cytidine diphosphate choline. Arzneimittelforschung. 1992;42:421-424.
9. Schäbitz WR, Weber J, Takano K, Sandage BW, Locke KW, Fisher M. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci. 1996;138:21-25.
10. Hazama T, Hasegawa T, Ueda S, Sakuma A. Evaluation of the effect of citicoline on poststroke hemiplegia employing a double-blind controlled trial. J Neurosci. 1980;11:211-225.
11. Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, Kameyama M, Omae T, Fujishima M, Sakuma A. Treatment of acute cerebral infarction with a choline precursor in a multi-center, double-blind, placebo-controlled study. Stroke. 1988;19:211-216.
12. D'Orlanda KJ, Sandage BW Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol Res. 1995;17:281-284.
13. Clark WM, Warach SJ, for the Citicoline Study Group. Randomized dose response trial of citicoline in acute ischemic stroke patients. Neurology. 1996;42(suppl 1):A425. Abstract.
14. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986;19:105-111.
15. Benveniste H, Jorgensen MB, Diemer NH, Hansen AJ. Calcium accumulation by glutamate receptor activation is involved in hippocampal cell damage after ischemia. Acta Neurol Scand. 1988;78: 529-536.
16. Ozyurt E, Graham D, Woodruff G, McCullogh J. Protective effect of the glutamate antagonist MK-801 reduces focal cerebral ischemia in the cat. J Cereb Blood Flow Metab. 1988;8:138-143.
17. Scatton B. Excitatory amino acid receptor antagonists: a novel treatment for ischemic cerebrovascular diseases. Life Sci. 1994;55: 2115-2124.
18. Siesjö BK. Pathophysiology and treatment of focal cerebral ischemia, part II: mechanisms of damage and treatment. J Neurosurg. 1992;77:337-354.
19. Minematsu K, Fisher M. MK-801 reduces extensive infarction after suture middle cerebral artery occlusion in rats. Cerebrovasc Dis. 1993;3:99-104.
20. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol. 1988;24:543-551.
21. Porter RH, Greenamyre JT. Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem. 1995;64:614-623.
22. Muir KW, Lees KR. Clinical experience with excitatory amino acid drugs. Stroke. 1995;26:503-513.
23. Koek W, Woods JH, Winger GD. MK-801, a proposed noncompetitive antagonist of excitatory AA transmission, produces phencyclidine-like behavioral effect in pigeons, rats, and rhesus monkeys. J Pharmacol Exp Ther. 1988;245:969-974.
24. Buchan AM, Lesiuk H, Barnes KA, Li H, Smith KE, Xue D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke. 1993;24(suppl I):I-148-I-152.
25. Silver B, Weber J, Fisher M. Review: medical therapy for ischemic stroke. Clin Neuropharmacol. 1996;19:101-128.
26. Minematsu K, Li L, Fisher M, Sotak CH, Davis MA, Fiandaca MS. Diffusion weighted magnetic resonance imaging: rapid and quantitative detection of focal brain ischemia. Neurology. 1992;42:235-240.
27. Koizumi J, Yoshida Y, Nakazawa T, Ooneda G. Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in recirculation can be introduced in the ischemic area. Jpn J Stroke. 1986;8:1-8.
28. Zea Longa E, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
29. Minematsu K, Li L, Sotak CH, Davis MA, Fisher M. Reversible focal ischemic injury demonstrated by diffusion-weighted magnetic resonance imaging. Stroke. 1992;23:1304-1311.
30. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990;10:290-293.
31. Lin T-N, He YY, Wu G, Khan M, Hsu CY. Effect of brain edema on infarct volume in a focal ischemia model in rats. Stroke. 1993; 24:117-121.
32. Trovarelli G, deMedio GE, Dorman RV, Piccinin GL, Horrocks LA, Porcellati G. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alteration of brain lipid in the gerbil. Neurochem Res. 1981;6:821-833.
33. Horrocks LA, Dorman RV, Dabrowiecki Z, Gorracci GF, Porcellati G. Citicoline and CDP-ethanolamine prevent the release of free fatty acids during brain ischemia. Prog Lipid Res. 1981;20: 531-534.
34. Isayama K, Pitts LH, Nishimura MC. Evaluation of 2,3,5-triphenyl-tetrazolium chloride staining to delineate rat brain infarcts. Stroke. 1991;22:1394-1398.
35. Cole DJ, Drummond JC, Ghazal EA, Shapiro HM. A reversible component of cerebral injury as identified by the histochemical stain 2,3,5-triphenyltetrazolium chloride (TTC). Acta Neuropathol (Berl). 1990;80:152-155.
36. Tatlisumak T, Takano K, Carano RAD, Opgenorth TJ, Fisher M. A novel endothelin antagonist, A-127722, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Cerebrovasc Dis. 1996;6(suppl 2):5.